Literature DB >> 3585493

High efficiency iodination of monoclonal antibodies for radiotherapy.

S J Mather, B G Ward.   

Abstract

A technique for labeling monoclonal antibodies (MoAb) with large activities of radioiodine using the reagent N-bromosuccinimide is described. This technique has been used to label three tumor-associated antibodies with an average labeling efficiency of greater than 90%. No significant damage to the antibody could be detected by enzyme linked immunosorbent assay (ELISA), performed immediately after the labeling procedure. Because high radiochemical purity can be achieved without the need postlabeling purification, the procedure is rapid and results in very low radiation doses to staff.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3585493

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

2.  Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Authors:  P N Hawkins; G A Tennent; P Woo; M B Pepys
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

3.  Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.

Authors:  P N Hawkins; R Wootton; M B Pepys
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis.

Authors:  Heni Rachmawati; Leonie Beljaars; Catharina Reker-Smit; Anne-miek M Van Loenen-Weemaes; Werner I Hagens; Dirk K F Meijer; Klaas Poelstra
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

5.  Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo.

Authors:  Jai Prakash; Ruchi Bansal; Eduard Post; Alie de Jager-Krikken; Marjolijn N Lub-de Hooge; Klaas Poelstra
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Studies of the structure and binding properties of hamster female protein.

Authors:  G A Tennent; M L Baltz; G D Osborn; P J Butler; G E Noble; P N Hawkins; M B Pepys
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

7.  Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?

Authors:  Julian D Gillmore; Winston L Hutchinson; Jeff Herbert; Alison Bybee; Daniel A Mitchell; Robert P Hasserjian; Ken-Ichi Yamamura; Misao Suzuki; Caroline A Sabin; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

8.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

Authors:  D M Vigushin; M B Pepys; P N Hawkins
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated.

Authors:  Werner I Hagens; Adriana Mattos; Rick Greupink; Alie de Jager-Krikken; Catharina Reker-Smit; Annemiek van Loenen-Weemaes; I Annette S H Gouw; Klaas Poelstra; Leonie Beljaars
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

10.  The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.

Authors:  B Ward; S Mather; J Shepherd; M Crowther; L Hawkins; K Britton; M L Slevin
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.